Literature DB >> 17654526

Tumor doubling time and local immune response to hepatic metastases from colorectal cancer.

Ayako Kito1, Kuniya Tanaka, Haruka Fujimaki, Masatoshi Nakazawa, Shinji Togo, Mutsuhiko Minami, Hiroshi Shimada.   

Abstract

BACKGROUND AND OBJECTIVES: A number of studies have investigated the role of tumor-infiltrating lymphocytes in cancer, yet the local immune response to hepatic colorectal cancer metastasis remains unclear. As the tumor doubling time (DT) of hepatic colorectal cancer metastases is a good index of tumor growth, we examined the correlation between tumor DT and the local immune response by phenotype in hepatic colorectal cancer metastases.
METHODS: Tumor DT and local immune response were examined in 20 patients with hepatic colorectal cancer metastases by analyzing tumor-infiltrating lymphocytes using flow cytometry or immunohistochemical studies. Tumor proliferative activity was also investigated by determining the expression levels of Ki-67 and proliferating cell nuclear antigen (PCNA).
RESULTS: Locally abundant populations of CD83(+) dendritic cells (DCs) and CD8(+) T cells were positively related to longer tumor DT (P < 0.05), as were abundant CD8(+) T cells having interferon-gamma-producing potentials (P < 0.05). There was no significant correlation between tumor cell expression levels of Ki-67 or PCNA and tumor DT.
CONCLUSIONS: Longer DT tumors have increased local populations of CD8(+) T cells and CD83(+) DCs even in hepatic colorectal cancer metastases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17654526     DOI: 10.1002/jso.20806

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  7 in total

1.  Prognostic significance of doubling time in patients undergoing radical surgery for metachronous peritoneal metastases of colorectal cancer.

Authors:  Hiroaki Miyake; Koji Murono; Hiroshi Nagata; Hiroaki Nozawa; Kazushige Kawai; Keisuke Hata; Toshiaki Tanaka; Takeshi Nishikawa; Yasutaka Shuno; Kazuhito Sasaki; Soichiro Ishihara
Journal:  Int J Colorectal Dis       Date:  2019-02-09       Impact factor: 2.571

2.  Tumor-Infiltrating Lymphocytes and Macrophages in Intrahepatic Cholangiocellular Carcinoma. Impact on Prognosis after Complete Surgery.

Authors:  Luca Vigano; Cristiana Soldani; Barbara Franceschini; Matteo Cimino; Ana Lleo; Matteo Donadon; Massimo Roncalli; Alessio Aghemo; Luca Di Tommaso; Guido Torzilli
Journal:  J Gastrointest Surg       Date:  2019-01-31       Impact factor: 3.452

3.  Recruitment of dendritic cells in human liver with metastases.

Authors:  M Gulubova; I Manolova; G Cirovski; D Sivrev
Journal:  Clin Exp Metastasis       Date:  2008-06-27       Impact factor: 5.150

4.  Rebound growth of hepatic colorectal metastases after neo-adjuvant chemotherapy: effect on survival after resection.

Authors:  Elizabeth Lim; Matthew G Wiggans; Golnaz Shahtahmassebi; Somaiah Aroori; Matthew J Bowles; Christopher D Briggs; David A Stell
Journal:  HPB (Oxford)       Date:  2016-05-20       Impact factor: 3.647

5.  Impact of Surgical Resection on Metachronous Metastases of Colorectal Cancer According to Tumor Doubling Time.

Authors:  Hiroaki Miyake; Koji Murono; Kazushige Kawai; Hiroaki Nozawa; Harufumi Maki; Kiyoshi Hasegawa; Jun Nakajima; Soichiro Ishihara
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 6.  The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review.

Authors:  A A P Slesser; P Georgiou; G Brown; S Mudan; R Goldin; P Tekkis
Journal:  Clin Exp Metastasis       Date:  2012-11-23       Impact factor: 5.150

7.  Prognostic value of intra-tumoral CD8+ /FoxP3+ lymphocyte ratio in patients with resected colorectal cancer liver metastasis.

Authors:  Kostandinos Sideras; Boris Galjart; Angela Vasaturo; Alexander Pedroza-Gonzalez; Katharina Biermann; Shanta Mancham; Alex L Nigg; Bettina E Hansen; Hans A Stoop; Guoying Zhou; Cornelis Verhoef; Stefan Sleijfer; Dave Sprengers; Jaap Kwekkeboom; Marco J Bruno
Journal:  J Surg Oncol       Date:  2018-06-07       Impact factor: 3.454

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.